Poor immune recovery following highly active antiretroviral treatment (HAART) represents a significant health problem affecting a large proportion (30%) of HIV-infected patients. Despite suppressing HIV replication, patients that are unable to sufficiently increase their CD4+ T cell numbers are at significant risk of clinical progression (AIDS-defining event or death). Currently there is a critical need to define the host genes that contribute to CD4+ T cell recovery in order to identify targets for immune modulating therapies. In addition, it is essential to identify biomarkers that can be used to tailor different HAART-regimens to the individual HIV-infected patient in order to maximize CD4+ T cell recovery and increase the utility of existing therapies.
In Aim 1 of this proposal differentially expressed genes between HIV-infected patients (exhibiting complete virological suppression) with a good (DCD4 3200 cells/mm3) versus a poor (DCD4 <200 cells/mm3) outcome after 48 weeks of HAART will be identified using microarrays. We hypothesize that genes contributing to immune recovery will induce CD4+ T cell proliferation and prevent apoptosis and this will be confirmed in vitro by siRNA knockdown and gene over expression analysis.
In Aim 2 we will expand upon our preliminary studies that showed gene expression prior to HAART can predict with 100% accuracy which HIV- infected patients progress to good versus poor outcome after 48 weeks of drug treatment. Gene expression classifiers predictive of immune recovery will be constructed exclusively for HIV-infected patients treated with a protease inhibitor (PI)-based HAART regimen, and then for patients treated with a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen. Using an innovative approach we will then use the PI-based gene expression classifier to determine if any of the poor outcome patients that were treated with an NNRTI- based regimen were predicted as having a good outcome under a PI-based regimen, and vice versa. In this way we will identify the total number of patients that were placed on the wrong regimen with respect to CD4+ T cell recovery. In the future we will be able to tailor different HAART regimens to the individual patient to increase the extent of immune recovery.
In Aim 3 the role of microRNAs (miRNAs) in immune recovery will be investigated. We hypothesize that miRNA degradation of mRNA targets represents one mechanism contributing to the differential gene expression between good and poor outcome groups (Aim 3A), and that a combination of miRNA expression with gene expression will result in more accurate classifiers (Aim 3B). When these studies are complete we will have identified the host genes (i.e. cytokines) that cause immune recovery in HIV-infected patients treated with HAART and may be formulated into immune modulating therapies in the future. We will also have developed gene expression biomarkers capable of guiding the treatment options for HIV-infected patients in order to maximize increases in CD4+ T cell numbers.

Public Health Relevance

Many HIV-infected patients fail to recover their immune system when placed on drug therapy. This research will identify patient genes that contribute to immune recovery and represent new targets for drugs that can be used to increase immune recovery. This proposal will also identify which drugs an HIV-infected patient should be treated with in order to maximize the extent of their immune recovery.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI087164-03
Application #
8196805
Study Section
AIDS Immunology and Pathogenesis Study Section (AIP)
Program Officer
Livnat, Daniella
Project Start
2009-12-15
Project End
2014-11-30
Budget Start
2011-12-01
Budget End
2012-11-30
Support Year
3
Fiscal Year
2012
Total Cost
$350,460
Indirect Cost
$102,960
Name
Veterans Medical Research Fdn/San Diego
Department
Type
DUNS #
933863508
City
San Diego
State
CA
Country
United States
Zip Code
92161
Beliakova-Bethell, Nadejda; Massanella, Marta; White, Cory et al. (2014) The effect of cell subset isolation method on gene expression in leukocytes. Cytometry A 85:94-104
Massanella, Marta; Singhania, Akul; Beliakova-Bethell, Nadejda et al. (2013) Differential gene expression in HIV-infected individuals following ART. Antiviral Res 100:420-8
Mehta, Sanjay R; Kosakovsky Pond, Sergei L; Young, Jason A et al. (2012) Associations between phylogenetic clustering and HLA profile among HIV-infected individuals in San Diego, California. J Infect Dis 205:1529-33
Cannella, Anthony P; Nguyen, Bichchau M; Piggott, Caroline D et al. (2011) A cluster of cutaneous leishmaniasis associated with human smuggling. Am J Trop Med Hyg 84:847-50
Mehta, Sanjay R; Nguyen, Vu T; Osorio, Georgina et al. (2011) Evaluation of pooled rapid HIV antibody screening of patients admitted to a San Diego Hospital. J Virol Methods 174:94-8
Mehta, Sanjay R; Wertheim, Joel O; Delport, Wayne et al. (2011) Using phylogeography to characterize the origins of the HIV-1 subtype F epidemic in Romania. Infect Genet Evol 11:975-9
Woelk, Christopher H; Singhania, Akul; Perez-Santiago, Josue et al. (2011) The utility of gene expression in blood cells for diagnosing neuropsychiatric disorders. Int Rev Neurobiol 101:41-63